Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Short-term cardiovascular effects of methylphenidate and adderall.

Findling RL, Short EJ, Manos MJ.

J Am Acad Child Adolesc Psychiatry. 2001 May;40(5):525-9.

PMID:
11349696
2.

A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.

Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL.

Pediatrics. 1999 Dec;104(6):1300-11.

PMID:
10585981
3.

A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ, Gnagy EM, Chronis AM, Onyango AN, Forehand G, Nguyen A, Waxmonsky J.

Pediatrics. 1999 Apr;103(4):e43.

PMID:
10103335
4.

Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder.

Manos MJ, Short EJ, Findling RL.

J Am Acad Child Adolesc Psychiatry. 1999 Jul;38(7):813-9.

PMID:
10405498
5.

Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder.

Findling RL, Short EJ, Manos MJ.

J Am Acad Child Adolesc Psychiatry. 2001 Dec;40(12):1441-7.

PMID:
11765290
6.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
7.

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.

Rösler M, Fischer R, Ammer R, Ose C, Retz W.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9. doi: 10.1007/s00406-008-0845-4. Epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):368.

PMID:
19165529
8.

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.

Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH.

Pediatrics. 2003 Nov;112(5):e404.

PMID:
14595084
9.

Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis.

Faraone SV, Biederman J, Roe C.

J Clin Psychopharmacol. 2002 Oct;22(5):468-73.

PMID:
12352269
10.

Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children.

Findling RL, Biederman J, Wilens TE, Spencer TJ, McGough JJ, Lopez FA, Tulloch SJ; SLI381.301 and .302 Study Groups.

J Pediatr. 2005 Sep;147(3):348-54.

PMID:
16182674
11.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

Pediatrics. 2001 Jun;107(6):E105.

PMID:
11389303
12.

An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension.

Wilens TE, Zusman RM, Hammerness PG, Podolski A, Whitley J, Spencer TJ, Gignac M, Biederman J.

J Clin Psychiatry. 2006 May;67(5):696-702.

PMID:
16841618
13.

Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.

Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J, Biederman J.

J Pediatr. 2009 Jul;155(1):84-9, 89.e1. doi: 10.1016/j.jpeds.2009.02.008. Epub 2009 Apr 25.

PMID:
19394037
14.
15.

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.

Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H.

J Clin Psychiatry. 2005 Feb;66(2):253-9.

PMID:
15705013
17.

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.

Biol Psychiatry. 2006 May 1;59(9):829-35. Epub 2005 Dec 20. Erratum in: Biol Psychiatry. 2007 Jun 15;61(12):1402.

PMID:
16373066
18.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
19.

Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.

Marchetti A, Magar R, Lau H, Murphy EL, Jensen PS, Conners CK, Findling R, Wineburg E, Carotenuto I, Einarson TR, Iskedjian M.

Clin Ther. 2001 Nov;23(11):1904-21.

PMID:
11768842
20.

Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder.

Pliszka SR, Matthews TL, Braslow KJ, Watson MA.

J Am Acad Child Adolesc Psychiatry. 2006 May;45(5):520-6.

PMID:
16670648

Supplemental Content

Support Center